Saudi Arabia making strides in biotechnology
At the BIO International Convention in Boston,
the King Faisal Specialist Hospital & Research Center (KFSHRC) announced a
landmark partnership with Germfree Laboratories to establish Saudi Arabia’s
first fully integrated modular manufacturing campus for advanced therapy
medicinal products (ATMPs).
The cutting-edge facility will be located on
KFSHRC’s Riyadh campus and is designed to accelerate the Kingdom’s Vision 2030
and its National Biotechnology Strategy. Both initiatives aim to position Saudi
Arabia as a global life sciences hub, with a strong focus on biomanufacturing
infrastructure and innovation.
Read More Neom
appoints official to lead efforts to become a global hub of biotechnology
The project is intended to rapidly scale Saudi
Arabia’s capacity to manufacture cell and gene therapies (CGTs) domestically
and support international clinical trials. It plays a vital role in the
Kingdom’s ambition to become a biotechnology leader by 2040.
“This initiative marks a historic
milestone—not only for our institution but for the entire Kingdom—aligning with
Vision 2030 and the National Biotechnology Strategy,” said Dr. Majid bin
Ibrahim Al Fayyadh, CEO of KFSHRC. “Our partnership with Germfree will create a
world-class ATMP campus that enhances access to transformative therapies,
attracts top scientific talent, and strengthens Saudi Arabia’s global position
in biotechnology.”
Kevin Kyle, CEO of Germfree Laboratories,
added, “KFSHRC’s leadership and strategic vision align perfectly with
Germfree’s mission to deliver agile, scalable infrastructure for advanced
therapies. Together, we’re building more than just a facility—we’re creating a
turnkey platform for the discovery and delivery of curative therapies for Saudi
Arabia, the region, and the world.”
The ATMP Manufacturing Campus will be
delivered as a GMP-compliant, modular solution, built off-site and deployed in
strategic phases. A new structure on the KFSHRC campus will accommodate
prefabricated cleanroom clusters, featuring 16 production suites designed for
multi-modal CGT manufacturing at both clinical and commercial scales. Full operational
readiness is targeted within 18 months of contract execution.
Read More Sascha
Berger to join as NEOM's Investment Director for Biotech
Saudi Arabia made a strong impression at BIO
2025, unveiling a two-story booth with a robust delegation and a packed
schedule of presentations. The country emphasized its growing commitment to the
biologics sector and its ambitions to emerge as a dominant player in the Middle
East and North Africa (MENA) region.
As regional investments in biotechnology
accelerate, Saudi Arabia—along with the UAE and other MENA nations—is
increasingly seen as a future powerhouse in global life sciences.
Source: Bio Process International
0 Comments